

# Dolors Colomer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1190639/publications.pdf>

Version: 2024-02-01

237  
papers

19,914  
citations

15466

65  
h-index

11581

135  
g-index

241  
all docs

241  
docs citations

241  
times ranked

22441  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. <i>Nature Genetics</i> , 2005, 37, 391-400.	9.4	1,710
2	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
3	ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 1764-1775.	13.9	1,194
4	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.	9.4	893
5	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	13.7	749
6	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 1236-1242.	9.4	525
7	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18250-18255.	3.3	488
8	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. <i>Nature Reviews Cancer</i> , 2007, 7, 750-762.	12.8	433
9	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.4	429
10	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. <i>Blood</i> , 2006, 107, 257-264.	0.6	417
11	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2003, 103, 1237-1243.	0.6	395
12	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 78-84.	0.6	356
13	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	1.7	345
14	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	0.6	340
15	Molecular pathogenesis of mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 3416-3423.	3.9	325
16	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.	0.6	260
17	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	0.8	253
18	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	0.6	246

#	ARTICLE	IF	CITATIONS
19	Molecular Subsets of Mantle Cell Lymphoma Defined by the <i>IGHV</i> Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. <i>Cancer Research</i> , 2012, 72, 5307-5316.	0.4	231
20	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. <i>Oncogene</i> , 2005, 24, 7213-7223.	2.6	202
21	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. <i>Haematologica</i> , 2006, 91, 169-75.	1.7	199
22	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. <i>Blood</i> , 2001, 98, 2771-2777.	0.6	184
23	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. <i>Blood</i> , 2007, 109, 4441-4449.	0.6	184
24	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1998, 92, 1406-1414.	0.6	182
25	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. <i>Genome Research</i> , 2014, 24, 212-226.	2.4	175
26	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2003, 107, 2428-2434.	1.6	169
27	In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999, 94, 2836-2843.	0.6	168
28	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 976-984.	1.2	163
29	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008, 112, 3130-3134.	0.6	154
30	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010, 116, e111-e117.	0.6	141
31	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3433-3438.	0.8	137
32	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. <i>Haematologica</i> , 2006, 91, 11-6.	1.7	135
33	Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. <i>Blood</i> , 2002, 99, 2969-2976.	0.6	131
34	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , 2020, 136, 1419-1432.	0.6	131
35	Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. <i>Blood</i> , 2003, 101, 3674-3680.	0.6	130
36	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006, 107, 4563-4569.	0.6	130

#	ARTICLE	IF	CITATIONS
37	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood</i> , 2013, 121, 2175-2185.	0.6	129
38	Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. <i>Cancer Research</i> , 2006, 66, 6947-6954.	0.4	127
39	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2831-2841.	3.2	123
40	Nonhepatosplenic $\hat{I}\hat{I}$ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1214-1225.	2.1	120
41	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and <i>JAK2 V617F</i> allele burden. <i>American Journal of Hematology</i> , 2009, 84, 102-108.	2.0	116
42	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1810-1816.	0.6	108
43	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. <i>Hepatology</i> , 2006, 44, 44-52.	3.6	103
44	The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. <i>Blood</i> , 2011, 117, 1270-1279.	0.6	102
45	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 2328-2334.	0.6	101
46	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	0.6	97
47	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. <i>Cancer Research</i> , 2005, 65, 2199-2206.	0.4	93
48	Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. <i>American Journal of Pathology</i> , 2004, 164, 501-510.	1.9	92
49	Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa. <i>Journal of Clinical Oncology</i> , 2003, 21, 1472-1479.	0.8	90
50	Involvement of CED-3/ICE Proteases in the Apoptosis of B-Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1997, 89, 3378-3384.	0.6	88
51	<i>In vitro</i> and <i>In vivo</i> Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts. <i>Clinical Cancer Research</i> , 2010, 16, 2046-2054.	3.2	87
52	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). <i>American Journal of Pathology</i> , 2002, 161, 957-968.	1.9	86
53	Mechanism of action and resistance to monoclonal antibody therapy. <i>Seminars in Oncology</i> , 2003, 30, 424-433.	0.8	84
54	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-cell chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 1998, 100, 142-146.	1.2	81

#	ARTICLE	IF	CITATIONS
55	Selective Inhibition of $\text{I}\kappa\text{B}$ Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level. <i>Journal of Immunology</i> , 2007, 178, 1923-1930.	0.4	81
56	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. <i>Cancer Research</i> , 2009, 69, 7071-7078.	0.4	78
57	Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1310-1322.	2.1	77
58	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. <i>Haematologica</i> , 2007, 92, 308-314.	1.7	76
59	Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters. <i>Clinical Cancer Research</i> , 2011, 17, 3956-3968.	3.2	76
60	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007, 136, 590-596.	1.2	75
61	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , 2005, 205, 507-513.	2.1	73
62	Type IMOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 140-145.	1.5	72
63	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015, 62, 72-74.	1.8	72
64	Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. <i>Clinical Cancer Research</i> , 2008, 14, 6907-6915.	3.2	69
65	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. <i>Blood</i> , 2002, 100, 4602-4608.	0.6	67
66	Clonal T-cell Populations and Increased Risk for Cytotoxic T-cell Lymphomas in B-CLL Patients. <i>American Journal of Surgical Pathology</i> , 2004, 28, 849-858.	2.1	67
67	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2008, 68, 10178-10186.	0.4	67
68	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. <i>Blood Advances</i> , 2020, 4, 5652-5665.	2.5	67
69	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. <i>Nature Communications</i> , 2021, 12, 651.	5.8	67
70	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. <i>Blood</i> , 2010, 116, 625-625.	0.6	64
71	Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. <i>Haematologica</i> , 2006, 91, 895-902.	1.7	63
72	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 22734-22749.	0.8	60

#	ARTICLE	IF	CITATIONS
73	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
74	Recurrent mutations of <i>NOTCH</i> genes in follicular lymphoma identify a distinctive subset of tumours. <i>Journal of Pathology</i> , 2014, 234, 423-430.	2.1	59
75	Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5278-5289.	3.2	58
76	The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2011, 179, 2601-2610.	1.9	57
77	Different distribution of <i>NOTCH1</i> mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 881-889.	1.5	57
78	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 <sup>int</sup> TCF-1 <sup>+</sup> CD8 <sup>+</sup> T <sub>H</sub> cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
79	<i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i> , 2016, 22, 2755-2764.	3.2	55
80	Control of chronic lymphocytic leukemia development by clonally-expanded CD8 <sup>+</sup> T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019, 33, 625-637.	3.3	55
81	Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon. <i>Journal of Clinical Oncology</i> , 2002, 20, 4032-4039.	0.8	53
82	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010, 95, 1317-1324.	1.7	53
83	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 1014-1019.	0.4	52
84	ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 726-734.	3.2	50
85	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. <i>Annals of Hematology</i> , 2008, 87, 269-276.	0.8	50
86	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. <i>Blood</i> , 2009, 114, 1563-1575.	0.6	50
87	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , 2017, 67, 501-507.	1.8	50
88	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , 2020, 105, 2205-2217.	1.7	47
89	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. <i>Clinical Chemistry</i> , 2013, 59, 938-948.	1.5	46
90	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. <i>Leukemia Research</i> , 2006, 30, 923-934.	0.4	45

#	ARTICLE	IF	CITATIONS
91	NF- $\kappa$ B as a therapeutic target in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 275-288.	1.5	44
92	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. <i>European Urology</i> , 2008, 54, 1363-1372.	0.9	40
93	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. <i>American Journal of Surgical Pathology</i> , 2016, 40, 192-201.	2.1	40
94	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	1.7	40
95	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. <i>Experimental Hematology</i> , 2003, 31, 204-210.	0.2	39
96	The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013, 98, 1739-1747.	1.7	39
97	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 1493-1505.	3.2	38
98	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 71-76.	0.6	37
99	Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 1873-1874.	0.6	36
100	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. <i>Modern Pathology</i> , 2015, 28, 1435-1447.	2.9	35
101	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. <i>American Journal of Hematology</i> , 2007, 82, 849-851.	2.0	33
102	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014, 99, e231-e234.	1.7	33
103	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <i>Haematologica</i> , 2014, 99, 873-880.	1.7	32
104	B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. <i>British Journal of Haematology</i> , 2014, 164, 570-578.	1.2	32
105	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021, 35, 2635-2649.	3.3	32
106	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , 2014, 5, 6788-6800.	0.8	32
107	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3754-3761.	3.2	31
108	p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective $\kappa$ B Kinase Inhibitor BMS-345541. <i>Clinical Cancer Research</i> , 2009, 15, 2767-2776.	3.2	31

#	ARTICLE	IF	CITATIONS
109	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 100-114.	3.3	31
110	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. <i>Journal of Clinical Investigation</i> , 2018, 128, 4132-4147.	3.9	31
111	High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 147, 36-43.	1.0	30
112	Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. , 2003, 56B, 8-15.		29
113	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. <i>Haematologica</i> , 2020, 105, 1032-1041.	1.7	29
114	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1086-1097.	1.5	28
115	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , 2017, 96, 81-85.	0.8	28
116	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 446.	3.5	28
117	Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020, 191, 52-61.	1.2	28
118	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017, 102, e360-e363.	1.7	27
119	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2311-2324.	3.3	27
120	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 717-722.	0.6	26
121	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 664-675.	2.6	26
122	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. <i>Journal of Hematology and Oncology</i> , 2018, 11, 112.	6.9	26
123	EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 3152-3162.	3.3	26
124	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206.	2.5	26
125	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000, 114, 786-792.	0.4	25
126	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 89-95.	1.8	25



#	ARTICLE	IF	CITATIONS
127	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in <i>in vivo</i> and <i>in vitro</i> models of mantle cell lymphoma. <i>Oncotarget</i> , 2014, 5, 726-739.	0.8	25
128	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
129	Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 586-597.	3.2	24
130	Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. <i>Autophagy</i> , 2013, 9, 115-117.	4.3	24
131	Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes. <i>Clinical Cancer Research</i> , 2014, 20, 393-403.	3.2	24
132	Disruption of Follicular Dendritic Cellsâ€“Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). <i>Clinical Cancer Research</i> , 2014, 20, 3458-3471.	3.2	24
133	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. <i>Nature Communications</i> , 2020, 11, 3390.	5.8	24
134	CD34+-enrichedâ€“CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders. <i>Experimental Hematology</i> , 2002, 30, 824-830.	0.2	23
135	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , 2004, 23, 8941-8949.	2.6	23
136	Detection of chromothripsisâ€“like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.	1.5	23
137	PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.	2.5	23
138	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 5507-5520.	0.8	23
139	Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature. <i>Transplantation</i> , 2004, 77, 311-313.	0.5	22
140	In vivo intratumoral Epsteinâ€“Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , 2014, 27, 1599-1611.	2.9	22
141	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	1.2	22
142	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , 2020, 39, 1185-1197.	2.6	22
143	Mantle cell lymphoma in Taiwan: Clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. <i>Pathology International</i> , 2006, 56, 440-448.	0.6	20
144	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851.	1.7	20

#	ARTICLE	IF	CITATIONS
145	Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. , 1996, 8, 311-318.		18
146	Î±-thalassaemia due to a single codon deletion in the Î±-1-globin gene. Computational structural analysis of the new Î±-chain variant. Human Mutation, 1998, 11, 412-412.	1.1	18
147	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. Stem Cells, 2016, 34, 581-587.	1.4	18
148	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-Î²B mutational status. Haematologica, 2017, 102, e447-e451.	1.7	18
149	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 132-136.	1.7	17
150	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. Haematologica, 2012, 97, 943-951.	1.7	17
151	Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma. Cancer Cell, 2014, 25, 7-9.	7.7	17
152	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	1.7	17
153	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. British Journal of Haematology, 2022, 196, 146-155.	1.2	17
154	Surface adenosine deaminase. Human Immunology, 1995, 42, 265-273.	1.2	16
155	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 141, 114-119.	1.0	16
156	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2064-2068.	0.6	16
157	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Scientific Reports, 2020, 10, 22153.	1.6	16
158	Stability of Conversion Factors for BCR-ABL Monitoring -â€ Implications for the Frequency of Validation Rounds. Blood, 2010, 116, 893-893.	0.6	16
159	Bcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget, 2015, 6, 21159-21172.	0.8	16
160	Translocation of Nucleoside Analogs Across the Plasma Membrane in Hematologic Malignancies. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1324-1340.	0.4	15
161	Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with <i>IGHV</i> mutational status, <i>NOTCH1</i> mutations and clinical significance. Genes Chromosomes and Cancer, 2013, 52, 920-927.	1.5	15
162	FIRST DESCRIPTION OF A FRAMESHIFT MUTATION IN THE Î± 1 GLOBIN GENE ASSOCIATED WITH Î±-THALASSAEMIA. British Journal of Haematology, 1997, 98, 47-50.	1.2	14

#	ARTICLE	IF	CITATIONS
163	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 557-561.	1.2	14
164	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3081-3089.	1.2	14
165	Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 1988, 27, 157-162.	2.0	13
166	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	0.8	13
167	Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 89-93.	1.0	12
168	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021, 13, 3900.	1.7	12
169	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , 2013, 4, 1919-1932.	0.8	12
170	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 1999, 191, 229-234.	1.4	11
171	TBET-expressing Th1 CD4 <sup>+</sup> T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E $\mu$ CLL mice. <i>British Journal of Haematology</i> , 2020, 189, 133-145.	1.2	11
172	Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species. <i>Current Pharmaceutical Design</i> , 2004, 10, 841-853.	0.9	10
173	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. <i>Leukemia Research</i> , 2005, 29, 595-597.	0.4	10
174	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. <i>Annals of Hematology</i> , 2014, 93, 797-802.	0.8	10
175	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 37-43.	1.5	10
176	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	3.3	10
177	Expression and mutational analyses of KIT and PDGFR $\alpha$ in sarcomatoid renal cell carcinoma. <i>Histopathology</i> , 2009, 55, 230-232.	1.6	9
178	Chronic nonspherocytic hemolytic anemia (CNSHA) and glucose 6 phosphate dehydrogenase (G6PD) deficiency in a patient with familial amyloidotic polyneuropathy (FAP). <i>Human Genetics</i> , 1989, 81, 161-164.	1.8	8
179	Quantitative Assessment of PML-RAR $\alpha$ and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. <i>Clinical Chemistry</i> , 2004, 50, 1088-1092.	1.5	8
180	Fluorescent Nucleoside Derivatives as a Tool for the Detection of Concentrative Nucleoside Transporter Activity Using Confocal Microscopy and Flow Cytometry. <i>Molecular Pharmaceutics</i> , 2015, 12, 2158-2166.	2.3	8

#	ARTICLE	IF	CITATIONS
181	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. <i>British Journal of Haematology</i> , 2017, 177, 147-150.	1.2	8
182	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2762-2773.	2.3	8
183	A new genetic abnormality leading to <i>TP53</i> gene deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 612-618.	1.2	7
184	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
185	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2059-2066.	1.2	6
186	Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3935-3935.	0.6	6
187	Molecular biology in acute leukemia. <i>Clinical and Translational Oncology</i> , 2006, 8, 550-559.	1.2	5
188	A putative enhancer in the <i>ATM</i> gene associated with chronic lymphocytic leukemia risk. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 887-895.	1.5	5
189	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.	0.6	5
190	Early B-cell precursor lymphoblastic leukaemia: response to FLAG and high-dose cytarabine with sorafenib after initial refractoriness. <i>British Journal of Haematology</i> , 2019, 185, 755-757.	1.2	5
191	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1217-1224.	1.2	5
192	Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. <i>Leukemia</i> , 2022, 36, 583-587.	3.3	5
193	Obatoclox (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma. <i>Blood</i> , 2006, 108, 832-832.	0.6	5
194	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. <i>Blood</i> , 2013, 122, 378-378.	0.6	5
195	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. <i>Blood</i> , 2014, 124, 4680-4680.	0.6	5
196	The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 1647-1647.	0.6	5
197	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. <i>Leukemia</i> , 2022, 36, 1879-1886.	3.3	5
198	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. <i>Leukemia Research</i> , 2011, 35, 1276-1278.	0.4	4

#	ARTICLE	IF	CITATIONS
199	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , 2014, 124, 1677-1677.	0.6	4
200	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. <i>Acta Haematologica</i> , 2013, 129, 65-71.	0.7	3
201	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1041-1052.	2.5	3
202	Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 462-462.	0.6	3
203	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Hla</i> , 2022, 99, 93-104.	0.4	3
204	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. <i>Haematologica</i> , 2020, 105, e484.	1.7	2
205	Follicular Dendritic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. <i>Blood</i> , 2013, 122, 3072-3072.	0.6	2
206	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1998, 92, 1406-1414.	0.6	2
207	CXCR5-Mediated Shaping of the Lymphoid Follicle in Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2014, 4, 1374-1376.	7.7	1
208	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , 2021, 13, 3150.	1.7	1
209	Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1085-1090.	2.5	1
210	The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982-2004).. <i>Blood</i> , 2004, 104, 5287-5287.	0.6	1
211	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclox) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2007, 110, 3464-3464.	0.6	1
212	BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.. <i>Blood</i> , 2009, 114, 1235-1235.	0.6	1
213	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010, 116, 894-894.	0.6	1
214	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). <i>Blood</i> , 2018, 132, 1385-1385.	0.6	1
215	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , 2021, 192, 1020-1025.	1.2	1
216	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , 2013, 4, 1919-1932.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Reply to Schmidt ?MYST3/CREBBP (MOZ/CBP) and CREBBP/MYST3 (CBP/MOZ) Transcripts in AML with t(8;16)(p11;p13)?. Genes Chromosomes and Cancer, 2005, 42, 209-209.	1.5	0
218	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. Genes Chromosomes and Cancer, 2012, 51, 1064-1065.	1.5	0
219	Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". Journal of Hepatology, 2021, 74, 252-254.	1.8	0
220	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. Blood, 2004, 104, 2054-2054.	0.6	0
221	Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.. Blood, 2004, 104, 2079-2079.	0.6	0
222	Severe Myelodysplasia with Monosomy 7 Developing during Imatinib Treatment of Philadelphia-Positive Chronic Myeloid Leukemia: Two Cases Evolving with Different Outcome.. Blood, 2005, 106, 4861-4861.	0.6	0
223	c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.. Blood, 2005, 106, 4820-4820.	0.6	0
224	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. Blood, 2005, 106, 3009-3009.	0.6	0
225	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. Blood, 2006, 108, 2707-2707.	0.6	0
226	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2348-2348.	0.6	0
227	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. Blood, 2006, 108, 3598-3598.	0.6	0
228	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. Blood, 2007, 110, 2532-2532.	0.6	0
229	The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.. Blood, 2009, 114, 3734-3734.	0.6	0
230	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. Blood, 2009, 114, 1113-1113.	0.6	0
231	The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. Blood, 2010, 116, 3918-3918.	0.6	0
232	B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.. Blood, 2010, 116, 1361-1361.	0.6	0
233	Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. Blood, 2015, 126, 3902-3902.	0.6	0
234	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018, 132, 4299-4299.	0.6	0
236	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4288-4288.	0.6	0
237	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 588-595.	0.8	0